ArticleEuropean journal of nuclear medicine and molecular imaging2024
Development of probes for radiotheranostics with albumin binding moiety to increase the therapeutic effects of astatine-211 (
Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- Macropa-Based 225Ac-Labeled RGD Peptides for Targeted Alpha Therapy.Molecular pharmaceutics · 2026Article
- Alpha and Beta Emitters in Translational Nuclear Medicine: Clinical Advances, Challenges, and Future Direction.International journal of molecular sciences · 2026Review
- Astatine-211-Towards In Vivo Stable Astatine-211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications.Medicinal research reviews · 2026Review
- Combination therapy of anEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Synthesis and Evaluation of Radiogallium-Labeled Peptide Probes for In Vivo Imaging of Legumain Activity.Molecules (Basel, Switzerland) · 2025Article
- Preclinical evaluation of [European journal of nuclear medicine and molecular imaging · 2025Article
- Development of Novel Integrin αACS medicinal chemistry letters · 2025Article
- Engineering a Radiohybrid PSMA Ligand with an Albumin-Binding Moiety and Pharmacokinetic Modulation via an Albumin-Binding Competitor for Radiotheranostics.Molecules (Basel, Switzerland) · 2025Article
- Enhancing the radionuclide theranostic concept through the radiohybrid approach.RSC medicinal chemistry · 2025Review
- Recent advances in spatio-temporally controllable systems for management of glioma.Asian journal of pharmaceutical sciences · 2024Review
- In vivo stableEJNMMI radiopharmacy and chemistry · 2024Article
- Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?European journal of nuclear medicine and molecular imaging · 2024Review
- The Different Strategies for the Radiolabeling of [Pharmaceutics · 2024Review
- Recent advances in the development ofAnalytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
purposeWe have developed probes for multiradionuclides radiotheranostics using RGD peptide ([
methodsBiodistribution experiments of [
resultsThe blood retention of [
conclusionThe functionality of APBA as ABM like IPBA, and the usefulness of [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.